Dylan joined GSK in 2012 as Head of Strategy for Emerging Markets and Asia-Pacific, and as a member of the EMAP Leadership Team. In this role he was a key driver of GSK’s Emerging Markets strategy, as well as leading major initiatives including GSK’s Africa 2020 investment programme. Dylan went on to hold the role of General Manager of the Kazakhstan and Central Asia cluster, and more recently led the Novartis transaction on behalf of the Global Pharma business. Dylan is a graduate of Oxford University and a pharmaceutical industry expert having 17 years experience in the sector. Before joining GSK, he held a number of senior Commercial and Corporate Development roles at General Electric (Healthcare) and Takeda Pharmaceuticals; he has also supported a number a number of global pharmaceutical companies as a Strategy Consultant and led two Pharmaceutical industry start-ups.